Your browser doesn't support javascript.
loading
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
Moreau, Philippe; van de Donk, Niels Wcj; Nahi, Hareth; Oriol, Albert; Nooka, Ajay K; Martin, Thomas; Rosinol, Laura; Karlin, Lionel; Benboubker, Lotfi; Mateos, Maria-Victoria; Popat, Rakesh; Martínez-López, Joaquín; Sidana, Surbhi; Delforge, Michel; Pei, Lixia; Trancucci, Danielle; Olyslager, Yunsi; Uhlar, Clarissa; Stephenson, Tara; Rampelbergh, Rian Van; Banerjee, Arnob; Kobos, Rachel; Usmani, Saad Z.
Afiliação
  • Moreau P; Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France.
  • van de Donk NW; Department of Hematology, Amsterdam University Medical Center, Vrije Universteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Nahi H; Karolinska University Hospital, Huddinge, Stockholm, Sweden.
  • Oriol A; Institut Català d'Oncologia & Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain.
  • Nooka AK; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • Martin T; University of California San Francisco, San Francisco, CA, USA.
  • Rosinol L; Hospital Clínic, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain.
  • Karlin L; Service d'Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
  • Benboubker L; Service d'Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours, France.
  • Mateos MV; University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro del Investigación del Cáncer, CIBERONC, Salamanca, Spain.
  • Popat R; Clinical Research Facility, National Institute for Health Research University College London Hospitals, NHS Foundation Trust, London, UK.
  • Martínez-López J; Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid, Spain.
  • Sidana S; Stanford University of Medicine, Stanford, CA, USA.
  • Delforge M; University of Leuven, Leuven, Belgium.
  • Pei L; Janssen Research & Development, Raritan, NJ, USA.
  • Trancucci D; Janssen Research & Development, Raritan, NJ, USA.
  • Olyslager Y; Janssen Research & Development, Antwerp, Belgium.
  • Uhlar C; Janssen Research & Development, Spring House, PA, USA.
  • Stephenson T; Janssen Research & Development, Spring House, PA, USA.
  • Rampelbergh RV; Janssen Research & Development, Antwerp, Belgium.
  • Banerjee A; Janssen Research & Development, Spring House, PA, USA.
  • Kobos R; Janssen Research & Development, Raritan, NJ, USA.
  • Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Future Oncol ; 19(12): 811-818, 2023 Apr.
Article em En | MEDLINE | ID: mdl-37132225
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article